Oncogene Downregulation by Mahanine Suppresses Drug-Sensitive and Drug-Resistant Lung Cancer and Inhibits Orthotopic Tumor Progression

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Nov 9

PMID 39518013

Authors

Raghuram Kandimalla

Disha N Moholkar

Suman Kumar Samanta

Neha Tyagi

Farrukh Aqil

Ramesh Gupta

Affiliations

Soon will be listed here.

Abstract

: Lung cancer is one of the deadliest cancers, and drug resistance complicates its treatment. Mahanine (MH), an alkaloid from has been known for its anti-cancer properties. However, its effectiveness and mechanisms in treating non-small cell lung cancer (NSCLC) remain largely unexplored. The present study aimed to investigate MH's effect on drug-sensitive and drug-resistant NSCLC and its potential mechanism of action. : We isolated MH from leaves and the purity (99%) was confirmed by HPLC, LC-MS and NMR. The antiproliferative activity of MH was determined using MTT and colony formation assays against drug-sensitive (A549 and H1299) and Taxol-resistant lung cancer cells (A549-TR). Western blot analysis was performed to determine MH's effects on various molecular targets. Anti-tumor activity of MH was determined against lung tumors developed in female NOD Scid mice injected with A549-Fluc bioluminescent cells (1.5 × 10) intrathoracically. : MH dose-dependently reduced the proliferation of all lung cancer cells (A549, H1299 and A549-TR), with IC50 values of 7.5, 5, and 10 µM, respectively. Mechanistically, MH arrested cell growth in the G0/G1 and G2/M phases of the cell cycle by inhibiting cyclin-dependent kinase 4/6 (CDK4/6) and cell division control 2 (CDC2) and induced apoptosis through the downregulation of B-cell leukemia/lymphoma 2 (BCL2) and B-cell lymphoma-extra large (BCL-XL). The apoptotic induction capacity of MH can also be attributed to its ability to inhibit pro-oncogenic markers, including mesenchymal-epithelial transition factor receptor (MET), phosphorylated protein kinase B (p-AKT), phosphorylated mammalian target of rapamycin (p-mTOR), survivin, rat sarcoma viral oncogene (RAS), myelocytomatosis oncogene (cMYC), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) levels. In vivo, MH (25 mg/kg b. wt.) significantly ( < 0.001) inhibited the growth of A549 lung cancer orthotopic xenografts in NOD Scid mice by 70%. : Our study provides new mechanistic insights into MH's therapeutic potential against NSCLC.

References

Giordano S, Ponzetto C, Di Renzo M, Cooper C, Comoglio P . Tyrosine kinase receptor indistinguishable from the c-met protein. Nature. 1989; 339(6220):155-6. DOI: 10.1038/339155a0. View

Shao D, Xue W, Krall E, Bhutkar A, Piccioni F, Wang X . KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014; 158(1):171-84. PMC: 4110062. DOI: 10.1016/j.cell.2014.06.004. View

Kabir A, Muth A . Polypharmacology: The science of multi-targeting molecules. Pharmacol Res. 2022; 176:106055. DOI: 10.1016/j.phrs.2021.106055. View

Kandimalla R, Das M, Barge S, Sarma P, Koiri D, Devi A . Variation in biosynthesis of an effective anticancer secondary metabolite, mahanine in Murraya koenigii, conditional on soil physicochemistry and weather suitability. Sci Rep. 2020; 10(1):20096. PMC: 7675983. DOI: 10.1038/s41598-020-77113-y. View

Kim R . Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005; 333(2):336-43. DOI: 10.1016/j.bbrc.2005.04.161. View

Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z . PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020; 11(9):797. PMC: 7515865. DOI: 10.1038/s41419-020-02998-6. View

Chen M, Yin X, Lu C, Chen X, Ba H, Cai J . Mahanine induces apoptosis, cell cycle arrest, inhibition of cell migration, invasion and PI3K/AKT/mTOR signalling pathway in glioma cells and inhibits tumor growth in vivo. Chem Biol Interact. 2018; 299:1-7. DOI: 10.1016/j.cbi.2018.11.009. View

Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R . Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. Lung Cancer Manag. 2014; 3(1):67-75. PMC: 4203662. DOI: 10.2217/lmt.13.72. View

Tran P, Fan A, Bendapudi P, Koh S, Komatsubara K, Chen J . Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One. 2008; 3(5):e2125. PMC: 2365560. DOI: 10.1371/journal.pone.0002125. View

10.

Chatterjee P, Seal S, Mukherjee S, Kundu R, Bhuyan M, Barua N . A carbazole alkaloid deactivates mTOR through the suppression of rictor and that induces apoptosis in lung cancer cells. Mol Cell Biochem. 2015; 405(1-2):149-58. DOI: 10.1007/s11010-015-2406-2. View

11.

Paul P, Gupta S, Bhatnagar S, Panguluri S, Darnay B, Choi Y . Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol. 2010; 191(7):1395-411. PMC: 3010064. DOI: 10.1083/jcb.201006098. View

12.

Das M, Kandimalla R, Gogoi B, Dutta K, Choudhury P, Devi R . Mahanine, A dietary phytochemical, represses mammary tumor burden in rat and inhibits subtype regardless breast cancer progression through suppressing self-renewal of breast cancer stem cells. Pharmacol Res. 2019; 146:104330. DOI: 10.1016/j.phrs.2019.104330. View

13.

Chen X, Duan N, Zhang C, Zhang W . Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. J Cancer. 2016; 7(3):314-23. PMC: 4747886. DOI: 10.7150/jca.13332. View

14.

Rasmi R, Sakthivel K, Guruvayoorappan C . NF-κB inhibitors in treatment and prevention of lung cancer. Biomed Pharmacother. 2020; 130:110569. DOI: 10.1016/j.biopha.2020.110569. View

15.

Li B, Torossian A, Li W, Schleicher S, Niu K, Giacalone N . A novel bioluminescence orthotopic mouse model for advanced lung cancer. Radiat Res. 2011; 176(4):486-93. PMC: 3199220. DOI: 10.1667/rr2565.1. View

16.

Koh H, Kim H, Kang S, Yoo T . Exosome-Based Drug Delivery: Translation from Bench to Clinic. Pharmaceutics. 2023; 15(8). PMC: 10459753. DOI: 10.3390/pharmaceutics15082042. View

17.

Salgia R . MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017; 16(4):555-565. DOI: 10.1158/1535-7163.MCT-16-0472. View

18.

Khan S, Fatima K, Aisha S, Malik F . Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024; 22(1):109. PMC: 10860306. DOI: 10.1186/s12964-023-01302-1. View

19.

Garcia-Gutierrez L, Delgado M, Leon J . MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes (Basel). 2019; 10(3). PMC: 6470592. DOI: 10.3390/genes10030244. View

20.

Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi P . Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers (Basel). 2022; 14(19). PMC: 9558974. DOI: 10.3390/cancers14194562. View